Sofosdac® is a pan-genotypic Direct Action Anti viral (DAA). It is indicated for the treatment of patients with chronic hepatitis C virus of all genotypes in adults.
| DCI | SOFOSBUVIR / DACLATASVIR |
|---|---|
| Dosage | 400/60 mg |
| Trade name | SOFOSDAC ® |
| Name of the originator | Sovaldi / Daklinza |
| Presentation | 28 tablets |
| Specialty | Hépatologie-AAD |
